Kornimate/medical-research-clean huggingface dataset:
feasibility of using ultrasound to track respiration motion

Conditions: Pancreatic Neoplasms

Summary: the purpose of this study is to evaluate the effectiveness of using ultrasound to image and track pancreas/duodenum motion during radiation therapy treatment delivery. also develop a workflow and process to allow the final ultrasound system to be used routinely by radiation therapists.

1. acquire 2d and 3d ultrasound images for 5 pancreatic cancer patients using the existing clarity system with a hand-held probe. the visibility of pancreas, duodenum, and other organs will be evaluated. based on this image acquisition experience, design and construct stands to hold the ultrasound probe. issues to be considered in the design include (i) avoiding the stand and probe blocking radiation beams, (ii) avoiding ultrasound going through the ribs, (iii) minimizing the effect of respiration motion. also explore building the probe into the immobilization device (e.g., alpha cradle) or using robotic arm. 2. acquire ultrasound images for 20 patients with pancreatic cancer treated in the department of radiation oncology department using the tools developed in aim 1. as the standard practice, the 4 dimensional ct (4dct) and 4 dimensional (4d) morphological and physiological mri (t1, t2, apparent diffusion coefficient, dwi) will be acquired for treatment planning, and a respiration-gated ct will be acquired immediately before the delivery of each fraction using an in-room ct or cone-beam ct for patient positioning. the ultrasound images may be acquired during initial simulation immediately before or after the planning 4dct and the daily gated ct, and during the treatment delivery in 2d, 3d and/or 4d modes. all raw ultrasound data will be stored. 3. process ultrasound data acquired above to evaluate the effectiveness of using ultrasound to image and to track pancreas/duodenum motion during the treatment delivery. the images will be processed to visualize pancreas and/or surrogates, such as the boundary between pancreas and duodenum, infusion catheter. to improve the visible appearance, elastography will be explored by processing the raw data collected in aim 2. existing software will be used, and may be modified if necessary, to segment and to register ultrasound with ct. a tool the investigators previous develop for multimodality registration will be used to register ultrasound with mri. anatomic markers, such as the boundary between pancreas head and duodenum, stent, infusion catheter, may be used for registration and/or motion tracking. 4. develop/modify workflow and process to allow the final system to be used routinely by radiation therapists. if necessary, user-friendly software tools will be developed/incorporated in the final system. 5. explore the use of doppler mode for tissue characterization and the potential of using it to image radiation effects.

Eligibility criteria:
inclusion criteria: * patients who will receive standard radiation therapy for pancreas cancer exclusion criteria: * patients who will receive standard radiation therapy for sites other than pancreas cancer

Keywords: ultrasound pancreatic neoplasms radiotherapy
the effect of environmental pollution on colorectal cancer

Conditions: Colorectal Carcinoma

Summary: colorectal cancer (crc) is one of the most common malignancies worldwide, and its main risk factors include age, genetic factors, inflammatory bowel diseases (e.g., ulcerative colitis and crohn's disease), unhealthy diets (e.g., high-fat, low-fibre diets), obesity, physical inactivity, smoking, and excessive alcohol consumption. the relationship between environmental pollution and colorectal cancer has received increasing attention in recent years. studies have shown that long-term exposure to fine particulate matter in the air, such as passive smoking, soot and oil smoke exposure, incense burning exposure, occupational exposure and outdoor work, pm2.5, pm10 and no2 may increase the risk of colorectal cancer. these particulate matter can enter the lungs through breathing and trigger a chronic inflammatory response in the systemic system, thus increasing the risk of cancer development. this study intends to determine the extent of air pollution's impact on colorectal cancer prognosis by analysing survival data of colorectal cancer patients in regions with different pollution levels. as well as to investigate the association between air pollution levels and postoperative recurrence in colorectal cancer patients, looking for possible mechanisms.


Eligibility criteria:
inclusion criteria: * age ≥18 years; * patients diagnosed with colorectal cancer by pathological biopsy before surgery; * patients did not undergo chemotherapy, radiotherapy, targeted and immunotherapy, etc. before enrolment; * willing to participate in this study and sign an informed consent form; * complete clinical data. exclusion criteria: * patients with primary malignant tumours other than colorectal cancer; * patients with systemic diseases, such as severe cardiopulmonary insufficiency, that affect the choice of treatment options; * patients who are not suitable for enrolment as assessed by the investigator; * incomplete clinical data.

Keywords: colorectal cancer environment airpollution greenness
preoperative transarterial chemoembolization for resectable hcc with portal venous invasion

Conditions: Resectable Hepatocellular Carcinoma With Portal Vein Tumor Thrombus

Summary: whether preoperative transarterial chemoembolization can prolong survival for the resectable hepatocellular carcinoma remains controversial, particularly in patients with portal vein tumor thrombi. this study designs to systematically identify and summarize the effect of preoperative tace for resectable hcc with portal venous invasion.

with various improvements in interventional radiology, since the 2005 practice guidelines issued by the american association for the study of liver diseases , transcatheter arterial chemoembolization has become one of the available locoregional therapies for hcc. transcatheter arterial chemoembolization, which generally performed in intermediate-stage hcc patients, involves injection of an embolizing agent into the hepatic artery to deprive the tumor of its major nutrient source via embolization of the nutrient artery, resulting in ischemic necrosis of the tumor. to prevent intrahepatic recurrence due to portal vein invasion of the hcc tumor, therapeutic strategies such as preoperative tace, and postoperative adjuvant chemotherapy have been tried. according to the latest and the most powerful evidence, however, preoperative tace is not routinely recommended for patients undergoing hepatectomy to treat resectable hcc , and tace may delay surgical treatment or decrease the resection volume of the liver, or it also may create a missed opportunity for surgical treatment. rather than subject all these patients to such an invasive procedure and put them at risk for missing opportunity for surgical treatment, it may be better to select optimal candidates to receive surgical resection. recent studies have even shown favorable long-term survival outcomes of hr in well-selected cases of hcc with pvtt. about whether preoperative transarterial chemoembolization is available for the resectable hepatocellular carcinoma with portal vein tumor thrombi, so far, has hardly been reported.

Eligibility criteria:
inclusion criteria: * a) age between 18 and 75 years, * b) hcc with no previous treatment, * c) the presence of major pvtt or less on imaging, * d) eastern co-operative group performance status 030 , * e) resectable disease exclusion criteria: * a) child-pugh class b or c liver cirrhosis, or evidence of hepatic decompensation including ascites, esophageal or gastric variceal bleeding or hepatic encephalopathy, or icgr-15 \>15%, * b) an american society of anesthesiologists (asa) score ≥ 3, * c) the presence of distant metastasis or other malignant diseases

Keywords: hepatocellular carcinoma; transarterial chemoembolization; hepatic resection; portal vein tumor thrombosis
transitional care interventions for patients with cirrhosis post-tips

Conditions: Fibrosis

Summary: the investigators conducted a randomized controlled trial to describe if multidisciplinary and patient-centered transitional care interventions for patients with cirrhosis post-tips can improve compliance behavior and reduce complications post-tips after discharge.


Eligibility criteria:
inclusion criteria: * clinical diagnosis of diagnosis of cirrhosis; * child-pugh score \<10; * informed consent. exclusion criteria: * age \<18 years; * right ventricular failure; * severe systemic infection; * hepatocellular carcinoma (hcc); * terminal disease; and * failure to provide written consent to participate in the study.
community based trial for amevive®

Conditions: Moderate to Severe Chronic Plaque Psoriasis

Summary: to evaluate the safety of treating subjects with up to 12 additional doses of alefacept.

male and female subjects at least 18 years of age with moderate to severe plaque psoriasis treated with 12 weeks of alefacept 15 mg im and who have not achieved the desired response. dosing groups: subjects will receive either 4, 8, or 12 doses of alefacept 15 mg im weekly immediately (within 14 days) following a standard 12-dose course of amevive® 15 mg im. determination of number of doses will be based on physician qualitative assessment at weeks 4 and 8.

Eligibility criteria:
inclusion criteria: 1. must give written informed consent. 2. must have had moderate, moderately severe or severe chronic plaque psoriasis as determined by the investigator prior to initial treatment (baseline) with amevive. 3. must be 18 years of age or older. 4. must have completed a standard 12-week course of amevive and have received at least 10 doses. 5. response to current amevive therapy must be less than a desired response as determined by the physician, and subject and some residual psoriasis must be present. exclusion criteria: 1. female subjects who are not postmenopausal for at least 1 year, surgically sterile, or not willing to practice effective contraception during the study. 2. nursing mothers, pregnant women, and women planning to become pregnant 3. current enrollment in any investigational study in which the subject is receiving any type of drug, biologic, or non-drug therapy. 4. treatment with another investigational drug, or approved therapy for investigational use, within 3 months of investigational drug administration. 5. treatment with systemic retinoids, systemic steroids, methotrexate, cyclosporine, azathioprine, thioguanine, etanercept, efalizumab, infliximab, adalimumab or mycophenolate mofetil or other systemic immunosuppressant agents within 4 weeks of investigational drug administration. 6. treatment with ultraviolet b (uvb) phototherapy or psoralen + ultraviolet a (puva), within 4 weeks of investigational drug administration. 7. serious local infection (e.g., cellulitis, abscess) or systemic infection (e.g., pneumonia, septicemia) within the 3 months prior to the first dose of investigational drug. 8. history of \>3 cutaneous squamous cell carcinomas or any systemic malignancy. 9. skin lesions suspicious for malignancy. 10. known hiv, viral hepatitis, or tuberculosis infection. 11. history of severe allergic or anaphylactic reactions. 12. alt or ast greater than three times the upper limit of normal. 13. significantly abnormal hematology (hemoglobin, hematocrit, platelets, white blood cells), as determined by the investigator. 14. cd4+ t lymphocyte count at screening visit less than 250 cells/mm3. 15. known hypersensitivity to amevive or any of its components. 16. subject's inability to comply with study requirements.

Keywords: extended dosing alefacept
supportive care during childbirth and well-being

Conditions: Psychological Well-being; Childbirth; Care Pattern, Maternal

Summary: the aim of this study is to evaluate the effects of continuous supportive care (icsc) at birth on some parameters of maternal psychological well-being.

this is a single-blind randomized controlled trial. data were collected from 80 women who gave birth in the obstetrics clinic of a state hospital in the south of turkey between december 2020 and june 2021. participants who met the inclusion criteria were informed about the purpose of the study and the procedures to be performed, informed consent was obtained from those who agreed to participate, and women were assigned to the groups in line with a computer-based randomization program with an allocation ratio of 1:1. block randomization could not be performed because of the different and long delivery processes. data were collected in both groups at birth (latent phase, active phase, and transitional phase), within 24 hours of birth, and 6th-8th postpartum days after hospital admission and at least one hour of care. collected by the first author. the consort directive was followed in the planning, implementation and writing of the research.

Eligibility criteria:
inclusion criteria: * the ages of 18-40 women, * at least primary school graduate, * mother tongue turkish, * single fetus, * term, * spontaneous birth, * cervical dilatation between 0-6 cm (latent phase) and without a condition that could prevent vaginal delivery. * primiparous and multiparous women * not have any disease or complication and agreed to participate in the study were included. exclusion criteria: * women who developed a complication with the fetus or themselves during delivery, * underwent emergency cesarean section, * not be reached during follow-ups by telephone, * wanted to withdraw from the study

Keywords: intrapartum supportive care birth trauma fear of childbirth maternal attachment perinatal well-being
study of rufinamide in pediatric subjects 1 to less than 4 years of age with lennox-gastaut syndrome inadequately controlled with other anti-epileptic drugs

Conditions: Lennox-Gastaut Syndrome

Summary: this study was designed to evaluate the cognitive effect, safety, and pharmacokinetics (pk) of rufinamide on lennox-gastaut syndrome (lgs) inadequately controlled in pediatric participants already taking other anti-epileptic drugs.


Eligibility criteria:
key inclusion: 1. clinical diagnosis of lgs, which might include the presence of a slow background electroencephalogram (eeg) rhythm, slow spikes-waves pattern (less than 3 hz), the presence of polyspikes; care should be taken not to include benign myoclonic epilepsy of infancy, atypical benign partial epilepsy (pseudo-lennox syndrome), or continuous spike-waves of slow sleep (csws). 2. on a fixed and documented dose of one to three concomitant regionally approved antiepileptic drugs (aeds) for a minimum of 4 weeks prior to randomization with an inadequate response to treatment. 3. consistent seizure documentation (i.e., no uncertainty of the presence of seizures) during the pre-randomization phase. key exclusion: 1. familial short qt syndrome 2. prior treatment with rufinamide within 30 days of baseline visit or discontinuation of rufinamide treatment due to safety issues related to rufinamide

Keywords: central nervous system
amiloride solution and tobramycin solution for inhalation for the eradication of burkholderia dolosa in patients with cystic fibrosis

Conditions: Cystic Fibrosis

Summary: the purpose of this research study is to determine if multiple doses of two inhaled drugs will help cystic fibrosis patients whose lungs are infected with a bacteria called burkholderia dolosa. the names of these drugs are tobramycin solution for inhalation and amiloride solution for inhalation. currently, treating patients with burkholderia dolosa infections is challenging because the bacteria is resistant to antibiotics. therefore, researchers are looking for drugs which, when taken with an antibiotic, will help the antibiotic to work more effectively.


Eligibility criteria:
inclusion criteria: * diagnosis of cystic fibrosis * two positive cultures for burkholderia dolosa lung infection exclusion criteria: * positive pregnancy test or currently breast feeding (if applicable) * known sensitivity to amiloride
evaluation of legionella pcr techniques for the routine diagnosis of legionellosis

Conditions: Legionellosis

Summary: the validity of molecular techniques for the diagnosis of legionellosis is not known. although pcr can detect legionella pneumophila (responsible for 80% of legionellosis) and other legionella species, this test is not recommended in standard guidelines to assess this diagnostic, by contrast to culture of sputum, serology and urine antigen. the aim of this study is to evaluate legionella pcr techniques, performed directly onto the sputum aspirates, for the routine diagnosis of pneumonia in adults' patients admitted to hospital. this study implicates 3 university hospitals (lyon, grenoble and saint-etienne) in collaboration with the french reference center of legionellosis for a previous duration of one year. in addition to the usual diagnostic tests that are performed when pneumonia is suspected, real-time pcr will be added for the detection and differentiation of legionella. hypothesizing the inclusion of 1000 pneumonia in this study, the predictable number of newly-detected legionellosis will be approximately 60 to 70 cases. according to a predefined algorithm, cases of legionellosis will be classified as definite or probable. sensitivity and specificity of the real-time pcr will be calculated according to this classification. this study is intended to validate real-time pcr as a tool for the rapid diagnosis of legionellosis, allowing to optimize the antibiotic treatment of pneumonia. pcr techniques can also contribute to the better detection and differentiation of legionella sp infections that are not documented accurately by routine microbiologic tests.


Eligibility criteria:
inclusion criteria: * written informed consent * patient affiliated to social insurance * community acquired or nosocomial pneumonia exclusion criteria: * no sputum aspirate

Keywords: legionellosis diagnosis of legionellosis pcr
detection of human beta cell death in type 1 diabetes mellitus (t1dm) by methylation specific polymerase chain reaction (pcr)

Conditions: Type 1 Diabetes Mellitus

Summary: to investigate the use of methylation-specific pcr (msp) assays to detect human beta cell-specific gene methylation patterns in serial blood samples drawn from newly diagnosed type 1 diabetics.

the study will follow 25 newly diagnosed type 1 diabetic patients from the onset of symptoms to one year post-diagnosis. a total of 11 fasting blood draws will be taken, the first near the time of diabetes diagnosis, then 2 weeks later, monthly for the next 6 months, and every other month until 12 months. each blood sample will be evaluated by the msp assay, as well as for measurement of fasting plasma glucose, hba1c, c-peptide, and autoantibodies. the study will also need 25 healthy volunteers to help us match some dna markers needed for this data. healthy volunteers will be se=matched healthy individuals who have one blood sample drawn.

Eligibility criteria:
inclusion criteria: healthy volunteers: * age \> 18 years of age, * otherwise healthy individuals with no cancer and not pregnant. type 1dm: * newly diagnosed type i diabetes, * age \> 18 years of age, * otherwise healthy individuals with no severe complications, no cancer, not pregnant, * willing and able to comply with the scheduled visits to the clinic for blood sampling, * remain under the continuing care of an endocrinologist.

Keywords: type i dm
a study to assess long-term outcomes of myocarditis following administration of covid-19 mrna vaccine (spikevax)

Conditions: Myocarditis

Summary: the main goal of this study is to characterize presentation, clinical course, and long-term outcomes of myocarditis temporally associated with administration of mrna-1273 (spikevax) covid-19 vaccine.

this is an observational cohort study that combines data collected directly from healthcare providers (hcp) with existing retrospective real-world data as captured in clinical electronic health record (ehr) and administrative claims data. vaccine exposure and case identification information will be obtained retrospectively from existing real-world data to identify cases of post-vaccine myocarditis (pvm) and ultimately vaccine-associated myocarditis (vam) for potential study inclusion. eligible participants will be identified and followed for up to 5 years until the end of the study period or loss to follow-up or death.

Eligibility criteria:
inclusion criteria: * participants with a diagnosis of myocarditis between december 18, 2020, and october 31, 2026, will be identified or who have a relevant combination of laboratory and clinical findings meeting the cdc case definition for probable or confirmed myocarditis will be included in the study. * participants will be required to have at least 30 days of medical history to assess spikevax exposure.

Keywords: mrna-1273 mrna-1273 vaccine sars-cov-2 sars-cov-2 vaccine coronavirus virus diseases messenger rna covid-19 covid-19 vaccine moderna
a multi-center, prospective registry to evaluate the continued safety and performance of clavicle plates

Conditions: Clavicle Fracture

Summary: the objective of the registry is to evaluate the continued safety and performance of arthrex clavicle plates used to treat clavicle fractures.

to assess safety, device-related adverse events will be reported and evaluated over the course of the study. to evaluate the performance imaging of the target area will be evaluated at three months postoperative. additionally, patient-reported outcomes will be evaluated at three months postoperative, 6 months postoperative, and one year postoperative using the visual analogue scale (vas), veterans rand 12-item health survey (vr-12), and american shoulder and elbow surgeons standardized shoulder assessment form (ases).

Eligibility criteria:
inclusion criteria: 1. the subject requires surgery using the arthrex clavicle plate for clavicle fracture. 2. the subject is 18 years of age or over. 3. the subject is not considered a vulnerable subject (i.e., child, pregnant, nursing, prisoner, or ward of the state). 4. subject signed informed consent and is willing and able to comply with all study requirements exclusion criteria: 1. insufficient quantity or quality of bone. 2. blood supply limitations and previous infections, which may retard healing. 3. foreign-body sensitivity. 4. any active infection or blood supply limitations. 5. conditions that tend to limit the patient's ability or willingness to restrict activities or follow directions during the healing period. 6. subjects that are skeletally immature.